Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Treasury Shares (2017 - 2026)

Denali Therapeutics has reported Treasury Shares over the past 9 years, most recently at $5.1 million for Q4 2025.

  • Quarterly Treasury Shares rose 24.13% to $5.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.1 million through Dec 2025, up 24.13% year-over-year, with the annual reading at $5.1 million for FY2025, 24.13% up from the prior year.
  • Treasury Shares was $5.1 million for Q4 2025 at Denali Therapeutics, down from $5.2 million in the prior quarter.
  • Over five years, Treasury Shares peaked at $5.2 million in Q3 2025 and troughed at $2.6 million in Q3 2021.
  • The 5-year median for Treasury Shares is $3.8 million (2023), against an average of $3.8 million.
  • Year-over-year, Treasury Shares skyrocketed 64.78% in 2021 and then increased 7.43% in 2024.
  • A 5-year view of Treasury Shares shows it stood at $2.6 million in 2021, then rose by 26.64% to $3.3 million in 2022, then grew by 9.14% to $3.6 million in 2023, then increased by 13.57% to $4.1 million in 2024, then increased by 24.13% to $5.1 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Treasury Shares are $5.1 million (Q4 2025), $5.2 million (Q3 2025), and $5.1 million (Q2 2025).